4.8 Article

Estrogen-Related Receptor α Expression and Function Is Associated with the Transcriptional Coregulator AIB1 in Breast Carcinoma

Journal

CANCER RESEARCH
Volume 69, Issue 12, Pages 5184-5190

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-08-3062

Keywords

-

Categories

Ask authors/readers for more resources

The significance of the estrogen-related receptor alpha (ERR alpha) as prognostic marker for poor clinical outcome in breast carcinoma has recently been reported. Transcriptional activity of nuclear receptors such as ERR alpha depends on coregulatory proteins. Thus, we compared the expression of different receptors, coregulators, and target genes on RNA and protein level in identical primary breast tumor samples (n = 48). We found a positive correlation between the transcripts of ERR alpha and AIB1 (amplified in breast cancer-1), a coactivator overexpressed in breast cancers and associated with resistance to antihormone treatment. These data were confirmed on protein level, studying an independent patient collection (n = 257). Expression of the estrogen-regulated gene pS2 was associated with ERR alpha only in tumors, where estrogen receptor (ER alpha) expression was low or absent. In ER alpha high expressing tumors, no correlation of ERR alpha and pS2 was observed. AIB1 interacts directly with ERR alpha as shown by fluorescence-resonance energy transfer, mammalian two-hybrid, and coimmunoprecipitation assays with endogenous proteins. It enhances ERR alpha transcriptional activity in ER alpha-negative breast cancer cell lines as shown in functional reporter gene assays. Blocking ERR alpha with an inverse agonist abolished interaction and coactivation by AIB1. Recruitment of both proteins to ERR alpha target gene promoters further supports the significance of their interaction. Our findings identify AIB1 as functionally relevant cofactor for ERR alpha in breast carcinoma. ERR alpha/AIB1 complexes may control estradiol-regulated genes in a hormone-independent manner. Accordingly, ERR alpha might be a rewarding target for treatment of endocrine-resistant tumors. [Cancer Res 2009;69(12):5186-93]

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available